What the approved product is for
Vyleesi is a prescription bremelanotide product for acquired, generalized hypoactive sexual desire disorder in premenopausal women who meet its diagnostic criteria. The manufacturer says it is not for men, postmenopausal women or improving sexual performance. A broad online category such as sexual wellness does not expand the approved indication.
Sources: Vyleesi — access, eligibility and safety, FDA — compounding questions and answers
What the advertised price covers
The manufacturer advertises a four-dose box for $99 for eligible patients whose commercial insurance does not cover Vyleesi. The assistance program has restrictions, including exclusion of patients insured through government-funded programs. This is not a universal uninsured cash price. The product page links the access process to BlinkRx and advertises free delivery.
Sources: Vyleesi — access, eligibility and safety, FDA — compounding questions and answers
What remains outside the package
The cost of a prescribing consultation needs to be checked separately. Four doses are the quantity sold under the offer, not a verified month of treatment or advice to use all four during a particular period. A compounded PT-141 offering should not be assumed to have the same approval status or clinical evidence as Vyleesi.
Sources: Vyleesi — access, eligibility and safety, FDA — compounding questions and answers
Clinical suitability comes first
The product is contraindicated in uncontrolled hypertension or known cardiovascular disease. Its labeling includes other warnings and adverse effects that a clinician should review. This price file does not diagnose a sexual-health condition, recommend a frequency of use or determine insurance eligibility. Confirm both the prescription and the manufacturer’s current offer terms.
Sources: Vyleesi — access, eligibility and safety, FDA — compounding questions and answers
Follow the evidence
Sources & price notes
Checked October 8, 2026. Provider pages document advertised terms; they do not independently establish clinical outcomes.
- Vyleesi — access, eligibility and safety ↗
Official public information; price and terms checked October 8, 2026.
- FDA — compounding questions and answers ↗
Clinical and regulatory context. A compounded preparation is not FDA-approved.